Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01426243
Other study ID # 2009-014921-17
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date July 2011
Est. completion date December 2017

Study information

Verified date February 2018
Source French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Main objective :

To develop the tools for evaluation of humoral and cell-mediated immunity after Yellow Fever Vaccine (YFV) and compare virological and immune responses in HIV-positive and HIV-negative individuals who had not been given YFV before.

Secondary objectives :

- To develop and assess ELISPOT technology for yellow fever and to measure the response within 7, 14, 28, 90 and 365 days of administration of YFV in 30 HIV negative subjects and 40 HIV positive subjects (CD4 > 350/mm3 under Highly Active Antiretroviral Therapy (HAART) for at least one year, with a viral load < 50 copies/mL since at least 6 months) in terms of : (1) seroconversion by fluorescence, (2) cytotoxic response in ELISPOT, (3) neutralizing antibody levels in Plaque reduction neutralization test (PRNT:reference method) and a new pseudotype based method, (4) post-vaccination viremia and (5) diversity of viral quasi-species.

- To assess the impact of YFV on the T-lymphocyte response against HIV by ELISPOT and viral load.


Description:

Method :

Clinical Trial Phase III, Multicentre protocol at Saint-Louis hospital, Bichat hospital and Cochin-Pasteur hospital, with CERVI, INSERM U 941 and SC10 collaboration.

Trial treatment : Yellow fever vaccination (STAMARIL)

Criterion :

Immuno-virologic: At J-7, J7, J28, M3 and M12 will be determined the levels of antibodies by fluorescence, at J0, J7, J28, M3 and M12 titles and neutralization with Prnt pseudotypes, the ELISPOT response anti-yellow fever, viremia with quantitative analysis and nucleotide sequences on phylogenetic strains of viremia. Titles and Amariles kinetics of viremia, neutralizing antibodies and ELISPOT will be considered as surrogate markers of response in terms of groups.

Clinical and biological tolerance: At all follows up will be measured the incidence of CDC classification events (for HIV+) and general and local reactions of degree ≥ 2 in the setting of the injection of STAMARIL®.

Schedule :

Date of first enrolment : third quarter 2011. Inclusion period : 18 months. For each subject, participation in this trial will be for 12 months.


Recruitment information / eligibility

Status Completed
Enrollment 71
Est. completion date December 2017
Est. primary completion date February 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Group 1: Voluntary HIV positive subjects

Inclusion Criteria:

- Adults under HAART for at least one year (and stable on treatment for at least 3 months prior to enrolment)

- > 350 CD4/mm3 (with half of them a nadir < 200 CD4/mm3) and a viral load < 50 copies/mL for at least 6 months.

- Patients were HCV negative or non-replicative and treated for at least 2 years with normal ALT and negative HBs antigen.

Exclusion Criteria:

- Previous vaccination against yellow fever or yellow fever Fluorescence anti-IgG positive.

- Administration of immunoglobulins < 3 months or any vaccine <1 month.

- Pregnancy ongoing or planned during the study.

- Coinfection with HCV virus untreated.

- HBs Ag positive.

- Hypersensitivity reaction to eggs / chicken protein; hereditary fructose intolerance.

- Immunosuppression, whether congenital, idiopathic or as a result of corticosteroids systemically (at doses = 20mg/d of prednisone), or due to radiation or antineoplastic older than 6 months.

- History of thymic dysfunction (including thymoma and thymectomy).

- For HIV + subjects: ART Celsentri or by other anti-CCR5.

Group 2: HIV negative subjects

Inclusion Criteria:

HIV and HCV negatives

Exclusion Criteria:

- Previous vaccination against yellow fever or yellow fever Fluorescence anti-IgG positive.

- Administration of immunoglobulins < 3 months or any vaccine <1 month.

- Other vaccinations should be deferred beyond M3.

- Pregnancy ongoing or planned during the study.

- Coinfection with HCV virus untreated.

- HBs Ag positive.

- Hypersensitivity reaction to eggs / chicken protein; hereditary fructose intolerance.

- Immunosuppression, whether congenital, idiopathic or as a result of corticosteroids systemically (at doses = 20mg/d of prednisone), or due to radiation or antineoplastic older than 6 months.

- History of thymic dysfunction (including thymoma and thymectomy).

- For HIV + subjects: ART Celsentri or by other anti-CCR5, coinfection with HCV virus untreated

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Yellow fever vaccination (STAMARIL)
Yellow fever vaccination (STAMARIL)
Yellow fever vaccination (STAMARIL)
Yellow fever vaccination (STAMARIL)

Locations

Country Name City State
France Voir Liste Des Centres Paris

Sponsors (1)

Lead Sponsor Collaborator
French National Agency for Research on AIDS and Viral Hepatitis

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immuno-virologic criterion - At Day-7 will be determined the levels of antibodies by fluorescence. DAY-7
Primary Immuno-virologic criterion At Day 0 will be determined titles and neutralization with Prnt pseudotypes, the ELISPOT response anti-yellow fever, viremia with quantitative analysis and nucleotide sequences on phylogenetic strains of viremia Day 0
Primary Immuno-virologic criterion At Day 28 will be determined titles and neutralization with Prnt pseudotypes, the ELISPOT response anti-yellow fever, viremia with quantitative analysis (if it's positive at day7) and nucleotide sequences on phylogenetic strains of viremia Day 28
Primary Immuno-virologic criterion At Month 3 will be determined fluorescence, PRNT and ELISPOT. Month 3
Primary Immuno-virologic criterion At Month 12 will be determined fluorescence, PRNT and ELISPOT. Month 12
Primary Immuno-virologic criterion At Day 7 will be determined titles and neutralization with Prnt pseudotypes, the ELISPOT response anti-yellow fever, viremia with quantitative analysis and nucleotide sequences on phylogenetic strains of viremia Day 7
Secondary Clinical and biological tolerance At Day -7 will be determined the levels of antibodies by fluorescence day -7
Secondary clinical and biological tolerance At Day 0: incidence of HIV+ event and general+local reactions of d°>2 after vaccination day 0
Secondary clinical and biological tolerance At Day7: incidence of HIV+ event and general+local reactions of d°>2 after vaccination day 7
Secondary clinical and biological tolerance At Day14:incidence of HIV+ event and general+local reactions of d°>2 after vaccination day 14
Secondary clinical and biological tolerance At Day 28:incidence of HIV+ event and general+local reactions of d°>2 after vaccination day 28
Secondary clinical and biological tolerance At Month3:incidence of HIV+ event and general+local reactions of d°>2 after vaccination month 3
Secondary clinical and biological tolerance At Month 12:incidence of HIV+ event and general+local reactions of d°>2 after vaccination month 12
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02135419 - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Phase 3
Active, not recruiting NCT02663856 - My Smart Age With HIV: Smartphone Self-assessment of Frailty
Completed NCT02921516 - Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings N/A
Completed NCT02846402 - Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda N/A
Completed NCT02663869 - Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
Completed NCT02659306 - Metformin Immunotherapy in HIV Infection Phase 1
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4
Completed NCT02564341 - Targeting Effective Analgesia in Clinics for HIV - Intervention N/A
Active, not recruiting NCT02302950 - A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas N/A
Terminated NCT02109224 - Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Phase 1
Completed NCT02269605 - Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment Phase 1
Completed NCT01852942 - Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV Phase 2
Completed NCT01830595 - Lactoferrin Treatment in HIV Patients Phase 2
Terminated NCT01902186 - Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir Phase 4
Completed NCT02118168 - Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002 N/A
Completed NCT02527135 - Text Messaging to Improve HIV Testing Among Young Women in Kenya N/A
Completed NCT02525146 - Birmingham Access to Care Study N/A
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Active, not recruiting NCT02602418 - Neural Correlates of Working Memory Training for HIV Patients N/A
Completed NCT01680094 - Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART Phase 1/Phase 2

External Links